SCHEMBL25833279

SCHEMBL25833279

CC#CCCCOCC(C)C

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 2/20 0.31
SPHK2 Q9NRA0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25468245 0.81 SPHK2 (0.30) SPHK1SPHK2
SCHEMBL3962044 0.75 SPHK1 (0.38) SPHK1SPHK2
SCHEMBL11858528 0.75 SPHK1 (0.42) SPHK1SPHK2
SCHEMBL25754404 0.75
SCHEMBL25754406 0.74 HTT (0.32)
SCHEMBL31086433 0.73 SPHK1 (0.44) SPHK1SPHK2
SCHEMBL10119365 0.73 SPHK1 (0.44) SPHK1SPHK2
SCHEMBL1016637 0.73
SCHEMBL1015468 0.71
SCHEMBL28382757 0.70 HSD17B10 (0.52) SPHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SPHK1 1872/4885SPHK2 1840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.